AAP
ADCT icon

Arax Advisory Partners’s ADC Therapeutics ADCT Stock Holding History

Arax Advisory Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18K Buy
+1,104
New +$3.22K ﹤0.01% 4910
2026
Q1 		– Sell
-17
Closed -$60 – 3774
2025
Q4 		$60 Sell
17
-655
-97% -$2.66K ﹤0.01% 3893
2025
Q3 		$2.69K Buy
+672
New +$2.12K ﹤0.01% 3039

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arax Advisory Partners's ADCT Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 1,104 shares worth $1.18K. The stake represents ﹤0.01% of the portfolio and ranks #4910 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ADCT as recently as Q4 2025.

Arax Advisory Partners first reported a position in ADCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.69K in Q3 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Arax Advisory Partners held 1,104 shares of ADC Therapeutics worth $1.18K as of Q2 2026.
  • ADC Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4910 holding.
  • Arax Advisory Partners first reported a position in ADC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's ADC Therapeutics position peaked at $2.69K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.